Home
Sessions
PQA 04: Breast Cancer, Patient Reported Outcomes/QoL/Survivorship, Nonmalignant Disease, Hematologic Malignancies, Palliative Care, and International/Global Oncology
A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab In Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

Sep 28

PQA 04 - PQA 04: Breast Cancer, Patient Reported Outcomes/QoL/Survivorship, Nonmalignant Disease, Hematologic Malignancies, Palliative Care, and International/Global Oncology

2735 - A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab In Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

03:00pm - 04:00pm ET

Presenter(s)

Ajay Fernandez, DO - UC Davis Comprehensive Cancer Center, Sacramento, CA